Acquisition Of The Drug Human Antithymocyte Immunoglobulin, In The Presentation Of 25Mg/5Ml, To Maintain The Hemopa Foundation'S Strategic Stock For The Care Of Patients Treated In The Hematology Outpatient Clinic With Diagnoses Of Severe Medullary Aplasia, As Detailed In The Terms Of Reference - Annex I

FUNDACAO CENTRO DE HEMOTERAPIA E HEMATOLOGIA DO PARA (HEMOPA) Brazil has Released a tender for Acquisition Of The Drug Human Antithymocyte Immunoglobulin, In The Presentation Of 25Mg/5Ml, To Maintain The Hemopa Foundation'S Strategic Stock For The Care Of Patients Treated In The Hematology Outpatient Clinic With Diagnoses Of Severe Medullary Aplasia, As Detailed In The Terms Of Reference - Annex I in Pharmaceuticals. The tender was released on Jan 25, 2024.

Country - Brazil

Summary - Acquisition Of The Drug Human Antithymocyte Immunoglobulin, In The Presentation Of 25Mg/5Ml, To Maintain The Hemopa Foundation'S Strategic Stock For The Care Of Patients Treated In The Hematology Outpatient Clinic With Diagnoses Of Severe Medullary Aplasia, As Detailed In The Terms Of Reference - Annex I

Deadline - login to view

GT reference number - 77500882

Product classification - Immunoglobulins